Salicylic acid treats acne vulgaris by suppressing AMPK/SREBP1 pathway in sebocytes
Acne vulgaris is a prevalent cutaneous disease characterized by a multifactorial pathogenic process including hyperseborrhea, inflammation, over‐keratinization of follicular keratinocytes and Propionibacterium acnes (P acnes) overgrowth. Salicylic acid (SA), a beta‐hydroxy acid, is frequently used i...
Saved in:
Published in | Experimental dermatology Vol. 28; no. 7; pp. 786 - 794 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Denmark
Wiley Subscription Services, Inc
01.07.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Acne vulgaris is a prevalent cutaneous disease characterized by a multifactorial pathogenic process including hyperseborrhea, inflammation, over‐keratinization of follicular keratinocytes and Propionibacterium acnes (P acnes) overgrowth. Salicylic acid (SA), a beta‐hydroxy acid, is frequently used in the treatment of acne. SA has been found to decrease skin lipids and to possess anti‐inflammatory properties. However, few studies have elucidated the mechanisms and pathways involved in such treatment of acne. In this study, we initially investigated the anti‐acne properties of SA in human SEB‐1 sebocytes. Treatment with SA decreased sebocyte lipogenesis by downregulating the adenosine monophosphate‐activated protein kinase (AMPK)/sterol response element‐binding protein‐1 (SREBP‐1) pathway and reduced inflammation by suppressing the NF‐κB pathway in these cells. Salicylic acid also decreased the cell viability of SEB‐1 by increasing apoptosis via the death signal receptor pathway. Subsequently, histopathological analysis of a rabbit ear acne model after application of SA for three weeks confirmed that SA suppressed the levels of cytokines and major pathogenic proteins around acne lesions, which supports the mechanisms suggested by our in vitro experiments. These results initially clarified that therapeutic activities of SA in acne vulgaris treatment could be associated with the regulation of SREBP‐1 pathway and NF‐κB pathway in human SEB‐1 sebocytes. |
---|---|
AbstractList | Acne vulgaris is a prevalent cutaneous disease characterized by a multifactorial pathogenic process including hyperseborrhea, inflammation, over‐keratinization of follicular keratinocytes and Propionibacterium acnes (P acnes) overgrowth. Salicylic acid (SA), a beta‐hydroxy acid, is frequently used in the treatment of acne. SA has been found to decrease skin lipids and to possess anti‐inflammatory properties. However, few studies have elucidated the mechanisms and pathways involved in such treatment of acne. In this study, we initially investigated the anti‐acne properties of SA in human SEB‐1 sebocytes. Treatment with SA decreased sebocyte lipogenesis by downregulating the adenosine monophosphate‐activated protein kinase (AMPK)/sterol response element‐binding protein‐1 (SREBP‐1) pathway and reduced inflammation by suppressing the NF‐κB pathway in these cells. Salicylic acid also decreased the cell viability of SEB‐1 by increasing apoptosis via the death signal receptor pathway. Subsequently, histopathological analysis of a rabbit ear acne model after application of SA for three weeks confirmed that SA suppressed the levels of cytokines and major pathogenic proteins around acne lesions, which supports the mechanisms suggested by our in vitro experiments. These results initially clarified that therapeutic activities of SA in acne vulgaris treatment could be associated with the regulation of SREBP‐1 pathway and NF‐κB pathway in human SEB‐1 sebocytes. Acne vulgaris is a prevalent cutaneous disease characterized by a multifactorial pathogenic process including hyperseborrhea, inflammation, over‐keratinization of follicular keratinocytes and Propionibacterium acnes (P acnes) overgrowth. Salicylic acid (SA), a beta‐hydroxy acid, is frequently used in the treatment of acne. SA has been found to decrease skin lipids and to possess anti‐inflammatory properties. However, few studies have elucidated the mechanisms and pathways involved in such treatment of acne. In this study, we initially investigated the anti‐acne properties of SA in human SEB‐1 sebocytes. Treatment with SA decreased sebocyte lipogenesis by downregulating the adenosine monophosphate‐activated protein kinase (AMPK)/sterol response element‐binding protein‐1 (SREBP‐1) pathway and reduced inflammation by suppressing the NF‐κB pathway in these cells. Salicylic acid also decreased the cell viability of SEB‐1 by increasing apoptosis via the death signal receptor pathway. Subsequently, histopathological analysis of a rabbit ear acne model after application of SA for three weeks confirmed that SA suppressed the levels of cytokines and major pathogenic proteins around acne lesions, which supports the mechanisms suggested by our in vitro experiments. These results initially clarified that therapeutic activities of SA in acne vulgaris treatment could be associated with the regulation of SREBP‐1 pathway and NF‐κB pathway in human SEB‐1 sebocytes. Acne vulgaris is a prevalent cutaneous disease characterized by a multifactorial pathogenic process including hyperseborrhea, inflammation, over-keratinization of follicular keratinocytes and Propionibacterium acnes (P acnes) overgrowth. Salicylic acid (SA), a beta-hydroxy acid, is frequently used in the treatment of acne. SA has been found to decrease skin lipids and to possess anti-inflammatory properties. However, few studies have elucidated the mechanisms and pathways involved in such treatment of acne. In this study, we initially investigated the anti-acne properties of SA in human SEB-1 sebocytes. Treatment with SA decreased sebocyte lipogenesis by downregulating the adenosine monophosphate-activated protein kinase (AMPK)/sterol response element-binding protein-1 (SREBP-1) pathway and reduced inflammation by suppressing the NF-κB pathway in these cells. Salicylic acid also decreased the cell viability of SEB-1 by increasing apoptosis via the death signal receptor pathway. Subsequently, histopathological analysis of a rabbit ear acne model after application of SA for three weeks confirmed that SA suppressed the levels of cytokines and major pathogenic proteins around acne lesions, which supports the mechanisms suggested by our in vitro experiments. These results initially clarified that therapeutic activities of SA in acne vulgaris treatment could be associated with the regulation of SREBP-1 pathway and NF-κB pathway in human SEB-1 sebocytes.Acne vulgaris is a prevalent cutaneous disease characterized by a multifactorial pathogenic process including hyperseborrhea, inflammation, over-keratinization of follicular keratinocytes and Propionibacterium acnes (P acnes) overgrowth. Salicylic acid (SA), a beta-hydroxy acid, is frequently used in the treatment of acne. SA has been found to decrease skin lipids and to possess anti-inflammatory properties. However, few studies have elucidated the mechanisms and pathways involved in such treatment of acne. In this study, we initially investigated the anti-acne properties of SA in human SEB-1 sebocytes. Treatment with SA decreased sebocyte lipogenesis by downregulating the adenosine monophosphate-activated protein kinase (AMPK)/sterol response element-binding protein-1 (SREBP-1) pathway and reduced inflammation by suppressing the NF-κB pathway in these cells. Salicylic acid also decreased the cell viability of SEB-1 by increasing apoptosis via the death signal receptor pathway. Subsequently, histopathological analysis of a rabbit ear acne model after application of SA for three weeks confirmed that SA suppressed the levels of cytokines and major pathogenic proteins around acne lesions, which supports the mechanisms suggested by our in vitro experiments. These results initially clarified that therapeutic activities of SA in acne vulgaris treatment could be associated with the regulation of SREBP-1 pathway and NF-κB pathway in human SEB-1 sebocytes. |
Author | Li, Xiaoxue Jiang, Xian Du, Dan Wen, Xiang Cong, Tianxin Lu, Jin He, Gu |
Author_xml | – sequence: 1 givenname: Jin surname: Lu fullname: Lu, Jin organization: Sichuan University – sequence: 2 givenname: Tianxin surname: Cong fullname: Cong, Tianxin organization: Sichuan University – sequence: 3 givenname: Xiang surname: Wen fullname: Wen, Xiang organization: Sichuan University – sequence: 4 givenname: Xiaoxue surname: Li fullname: Li, Xiaoxue organization: Sichuan University – sequence: 5 givenname: Dan surname: Du fullname: Du, Dan organization: Sichuan University – sequence: 6 givenname: Gu orcidid: 0000-0002-1536-8882 surname: He fullname: He, Gu email: hegu@scu.edu.cn organization: Sichuan University and Collaborative Innovation Center for Biotherapy – sequence: 7 givenname: Xian surname: Jiang fullname: Jiang, Xian email: jennyxianj@163.com organization: Sichuan University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30972839$$D View this record in MEDLINE/PubMed |
BookMark | eNpdkVtLw0AQhRep2Is--AdkwRdf0u4lm80-1lovWLFYBd_CJpnUlDSJ2cSaf-_2og8ODOfAfAzDnD7q5EUOCJ1TMqS2RvAdDylX3D1CPeoR4hCPiQ7qEUU8x5NEdFHfmBUhVHIpTlCXEyWZz1UPLRY6S6PWNtZRGuO6Al0b63PAX0221FVqcNhi05RlBcak-RKPn-aPo8XL9HpOcanrj41ucZpjA2ERtTWYU3Sc6MzA2UEH6O12-jq5d2bPdw-T8cxZcVe4jhDUBR6rSPqUMKI0owAgeSJplGgdCYhDQdRWPaJpGAqZKMb9iIIrNfP4AF3t95ZV8dmAqYN1aiLIMp1D0ZiAMSIVF9z1LXr5D10VTZXb6yzlcqY81xeWujhQTbiGOCirdK2rNvh9lwVGe2CTZtD-zSkJtjkENodgl0Mwfb_ZGf4DaKp6aw |
ContentType | Journal Article |
Copyright | 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
Copyright_xml | – notice: 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd – notice: 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
DBID | NPM 7T5 H94 K9. NAPCQ 7X8 |
DOI | 10.1111/exd.13934 |
DatabaseName | PubMed Immunology Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitle | PubMed AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Immunology Abstracts MEDLINE - Academic |
DatabaseTitleList | AIDS and Cancer Research Abstracts PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1600-0625 |
EndPage | 794 |
ExternalDocumentID | 30972839 EXD13934 |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: National Natural Science Foundation of China funderid: 21772131; 81872535 – fundername: the Fundamental Research Funds of Science & Technology Department of Sichuan Province funderid: 2019YFSY0004; 2017JY0075 – fundername: National Natural Science Foundation of China grantid: 21772131 – fundername: the Fundamental Research Funds of Science & Technology Department of Sichuan Province grantid: 2019YFSY0004 – fundername: National Natural Science Foundation of China grantid: 81872535 – fundername: the Fundamental Research Funds of Science & Technology Department of Sichuan Province grantid: 2017JY0075 |
GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 1OB 1OC 29G 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAKAS AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHEFC AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 CYRXZ D-6 D-7 D-E D-F DC6 DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EBC EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TUS UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR XG1 YFH YUY ZZTAW ~IA ~WT AGHNM NPM 7T5 AAMMB AEFGJ AEYWJ AGXDD AGYGG AIDQK AIDYY H94 K9. NAPCQ 7X8 |
ID | FETCH-LOGICAL-j3454-5514e3d9c7810209a21eee73f71cfaac5edb509c5ed60a1bb57f9238c1e47a263 |
IEDL.DBID | DR2 |
ISSN | 0906-6705 1600-0625 |
IngestDate | Fri Jul 11 00:28:57 EDT 2025 Fri Jul 25 10:13:03 EDT 2025 Thu Apr 03 07:08:07 EDT 2025 Wed Jan 22 16:42:06 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Keywords | NF-κB acne vulgaris salicylic acid sebocyte inflammation SREBP-1 |
Language | English |
License | 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-j3454-5514e3d9c7810209a21eee73f71cfaac5edb509c5ed60a1bb57f9238c1e47a263 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0002-1536-8882 |
PMID | 30972839 |
PQID | 2243296485 |
PQPubID | 2045157 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_2207935348 proquest_journals_2243296485 pubmed_primary_30972839 wiley_primary_10_1111_exd_13934_EXD13934 |
PublicationCentury | 2000 |
PublicationDate | July 2019 |
PublicationDateYYYYMMDD | 2019-07-01 |
PublicationDate_xml | – month: 07 year: 2019 text: July 2019 |
PublicationDecade | 2010 |
PublicationPlace | Denmark |
PublicationPlace_xml | – name: Denmark – name: Chichester |
PublicationTitle | Experimental dermatology |
PublicationTitleAlternate | Exp Dermatol |
PublicationYear | 2019 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 2004; 101 1997; 336 2015; 18 2000; 28 2017; 26 2000; 25 2018; 106 2015; 468 2015; 51 2002; 99 2008; 9 2016; 74 2008; 34 2008; 128 2002; 82 2008; 74 2003; 19 2015; 8 2007; 57 2018; 27 2016; 36 2016; 12 1998; 37 2004; 113 2015; 135 2017; 35 2004; 292 2015; 21 2002; 129 2013; 133 2008; 118 2014; 13 2018; 74 2006; 126 2012; 336 2016; 25 2016; 9 2005; 14 |
References_xml | – volume: 14 start-page: 143 year: 2005 publication-title: Exp. Dermatol. – volume: 51 start-page: 13113 year: 2015 publication-title: Chem. Commun. – volume: 336 start-page: 918 year: 2012 publication-title: Science – volume: 133 start-page: 429 year: 2013 publication-title: J. Invest. Dermatol. – volume: 128 start-page: 1286 year: 2008 publication-title: J. Invest. Dermatol. – volume: 74 start-page: S5 issue: suppl year: 2008 publication-title: Indian J. Dermatol. Venereol. Leprol. – volume: 27 start-page: 993 year: 2018 publication-title: Exp. Dermatol. – volume: 28 start-page: 27 year: 2000 publication-title: Nucleic Acids Res. – volume: 101 start-page: 11245 year: 2004 publication-title: Proc. Natl Acad. Sci. USA – volume: 126 start-page: 2178 year: 2006 publication-title: J. Invest. Dermatol. – volume: 9 start-page: 40 year: 2016 publication-title: J. Clin. Aesthet. Dermatol. – volume: 25 start-page: 25 year: 2000 publication-title: Nat. Genet. – volume: 74 start-page: 414 year: 2018 publication-title: Acta Biomater. – volume: 19 start-page: 1 year: 2003 publication-title: Adv. Dermatol. – volume: 118 start-page: 1468 year: 2008 publication-title: J. Clin. Investig. – volume: 9 start-page: 955 year: 2008 publication-title: Expert Opin. Pharmacother. – volume: 27 start-page: 30 year: 2018 publication-title: Exp. Dermatol. – volume: 25 start-page: 477 year: 2016 publication-title: Exp. Dermatol. – volume: 82 start-page: 104 year: 2002 publication-title: Acta Derm. Venereol. – volume: 113 start-page: 1168 year: 2004 publication-title: J. Clin. Investig. – volume: 99 start-page: 7148 year: 2002 publication-title: Proc. Natl Acad. Sci. USA – volume: 74 start-page: 945 year: 2016 publication-title: J. Am. Acad. Dermatol. – volume: 34 start-page: 45 year: 2008 publication-title: Dermatol. Surg. – volume: 18 start-page: 723 year: 2015 publication-title: Cell Host Microbe – volume: 336 start-page: 1156 year: 1997 publication-title: N. Engl. J. Med. – volume: 468 start-page: 125 year: 2015 publication-title: Biochem. J. – volume: 21 start-page: 18100 year: 2015 publication-title: Chemistry – volume: 126 start-page: 1226 year: 2006 publication-title: J. Invest. Dermatol. – volume: 36 start-page: 983 year: 2016 publication-title: Med. Res. Rev. – volume: 8 start-page: 455 year: 2015 publication-title: Clin. Cosmet. Investig. Dermatol. – volume: 13 start-page: 15 year: 2014 publication-title: J. Cosmet. Dermatol. – volume: 35 start-page: 179 year: 2017 publication-title: Clin. Dermatol. – volume: 57 start-page: 222 year: 2007 publication-title: J. Am. Acad. Dermatol. – volume: 135 start-page: 1491 year: 2015 publication-title: J. Invest. Dermatol. – volume: 106 start-page: 1727 year: 2018 publication-title: Biomed. Pharmacother. – volume: 25 start-page: 701 year: 2016 publication-title: Exp. Dermatol. – volume: 129 start-page: 933 year: 2002 publication-title: Ann. Dermatol. Venereol. – volume: 292 start-page: 726 year: 2004 publication-title: JAMA – volume: 26 start-page: 798 year: 2017 publication-title: Exp. Dermatol. – volume: 12 start-page: 1540 year: 2016 publication-title: Mol. BioSyst. – volume: 37 start-page: 335 year: 1998 publication-title: Int. J. Dermatol. |
SSID | ssj0017375 |
Score | 2.4803717 |
Snippet | Acne vulgaris is a prevalent cutaneous disease characterized by a multifactorial pathogenic process including hyperseborrhea, inflammation, over‐keratinization... Acne vulgaris is a prevalent cutaneous disease characterized by a multifactorial pathogenic process including hyperseborrhea, inflammation, over-keratinization... |
SourceID | proquest pubmed wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 786 |
SubjectTerms | Acids Acne acne vulgaris Adenosine kinase AMP Apoptosis Cell viability Cytokines Inflammation Keratinization Keratinocytes Kinases Lipids Lipogenesis NF‐κB Protein kinase Salicylic acid sebocyte Skin SREBP‐1 Sterol regulatory element-binding protein |
Title | Salicylic acid treats acne vulgaris by suppressing AMPK/SREBP1 pathway in sebocytes |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fexd.13934 https://www.ncbi.nlm.nih.gov/pubmed/30972839 https://www.proquest.com/docview/2243296485 https://www.proquest.com/docview/2207935348 |
Volume | 28 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3PS-QwFH6IB_Gy649dd9SVLOzBS8fWJE2DJ11HZBdFnBXmsFCSNJFR6IidquNf70vaKe6yB_FQGkgK7Ute3pe-L18AvssCgwbNXCSdDGlGLKWGRbGQBiNSVmgX2Bbn6ekV-zniowU4mO-FafQhuh9u3jPCfO0dXOnqlZPbp6KP8IV6LVDP1fKA6LKTjkoEDSK7scQVcypi3qoKeRZP9-T_UOXfIDVEmZOP8Gf-fg255LZfT3XfPP8j3fjOD1iBDy36JIfNcFmFBVuuwdJZm19fh-FQeZlgvIgy44IEGnqF5dKSh9rv-hhXRM9IVd81BNrymhyeXfzaG14Oji4S4s83flQzMi5JhROZmSGQ_QRXJ4PfP06j9tiF6IYyziKPoSwtpBEZoo9Yqv3EWiuoE4lxShluC40ww9_TWCVac-EQJmYmsUyo_ZR-hsVyUtovQBRLCpfFxmHQY0oVWaw4E1pyK5gzMunB9rwD8tZ3qhxBBfXJ4Iz34FtXjaPepzJUaSe1b-OF_ThlWQ82mo7L7xp5jpx6RSLEfT3YDebvKubrHTR8HgyfD0bHobD59qZbsIyYSTaM3W1YnN7X9ivikqneCQPwBQj23N4 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3Pb9MwFH4aQwIujN8rjGEkkLikJLUdxwcOG-3U0XWa1k3qLTiOjbpJ2bQ0jPI37V_hf9qzk0YMceCyA4colmxFsZ-f32f782eAdzLHoEETG0gr_TYjpmLNglBIjREpyTPr2Rb78fCYfZny6QpcLc_C1PoQ7YKb8ww_XjsHdwvSv3m5-ZF3Eb9Q1lAqR2ZxiRO28tNuH637vtfbGRx9HgbNnQLBCWWcBQ4gGJpLLRIMraFUvcgYI6gVkbZKaW7yDGOoe8ehirKMC4sYKNGRYUL1YorfvQN33Q3iTqm_f9iKVUWCelnfUOIcPRYhb3SMHG-o_dW_4dibsNjHtZ01-LVskZrOctqt5llX__xDLPJ_abJH8LAB2GSr9ojHsGKKJ3Bv3FAInsJkopwSMj5E6VlOPNO-xHRhyPfKHWyZlSRbkLI6rznCxTeyNT4YfZwcDrYPIuKucL5UCzIrSIljtV4gVn8Gx7dSpeewWpwVZh2IYlFuk1BbjOtMqTwJFWcik9wIZrWMOrCxtHjaDA9liriJuv3uhHfgbZuNju12a1RhzipXxmkXcsqSDryoe0p6XiuQpNSJLiG07cAHb-82YzmlQ0On3tDpYNr3iZf_XvQN3B8ejffSvd390St4gBBR1gTlDVidX1TmNcKwebbpez-Br7fdd64BZaY7QQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LbtQwFL0qRarY8H4MFDASSGwyJGM7jhcsCjOjlqHVqEOl2QXHDzStlI7IhDL8Er_CR3HtZCJALNh0wSKKpWtFia-v73F8fAzwXBpMGjRzkXQyLDNiKdUsioXUmJEyU7jAtjhK90_Yuzmfb8H3zV6YRh-i--HmIyOM1z7Al8b9EuT2q-kjfKGsZVRO7PoC52vV64MhOvfFYDAefXi7H7VHCkSnlHEWeXxgqZFaZJhZY6kGibVWUCcS7ZTS3JoCU6i_p7FKioILhxAo04llQg1Sis-9AldZGkt_TsTwuNOqSgQNqr5oSKNUxLyVMfK0oe5V_wZjf0fFIa2Nb8CPTYM0bJazfr0q-vrbH1qR_0mL3YTrLbwme0083IItW96GncOWQHAHZjPldZDxIkovDAk8-wrLpSVfar-tZVGRYk2qetkwhMtPZO9wOnk1Ox69mSbEH-B8odZkUZIKR2q9RqR-F04u5ZPuwXZ5XtoHQBRLjMti7TCrM6VMFivORCG5FcxpmfRgd-PwvB0cqhxRE_Wr3RnvwbPOjGHt12pUac9rX8crF3LKsh7cbzpKvmz0R3LqJZcQ2PbgZXB3Z9hM6NDReXB0PpoPQ-Hhv1d9CjvT4Th_f3A0eQTXEB_Khp28C9urz7V9jBhsVTwJfZ_Ax8vuOj8BWo858A |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Salicylic+acid+treats+acne+vulgaris+by+suppressing+AMPK%2FSREBP1+pathway+in+sebocytes&rft.jtitle=Experimental+dermatology&rft.au=Lu%2C+Jin&rft.au=Cong%2C+Tianxin&rft.au=Wen%2C+Xiang&rft.au=Li%2C+Xiaoxue&rft.date=2019-07-01&rft.issn=0906-6705&rft.eissn=1600-0625&rft.volume=28&rft.issue=7&rft.spage=786&rft.epage=794&rft_id=info:doi/10.1111%2Fexd.13934&rft.externalDBID=10.1111%252Fexd.13934&rft.externalDocID=EXD13934 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0906-6705&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0906-6705&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0906-6705&client=summon |